StockWatch
·

VISHNU CHEMICALS LTD. Q2 FY27 Results

VISHNUQ2 FY27 Results
Filing
Result:Weak· Market: Crashed#Margin expansion

Outlook: Cautiously Optimistic · Guidance: Cut

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue429.530.9%7.1%
Total Income439.091.6%7.0%
Expenditure390.600.1%7.1%
PBT48.4912.0%5.9%
Net Profit35.5710.3%8.2%
OPM14.91%0.20pp0.40pp
NPM8.10%0.78pp0.09pp
EPS5.2810.4%8.2%
View full financials

Revenue (+7.1%) and adjusted PAT (+8.2%) grew modestly with a slight OPM/NPM uptick, in-line and unremarkable for the chemicals sector with no real surprise.

VISHNU CHEMICALS · Q2 FY27 · THE VERDICT

The ₹35.6 Crore Quarter: Steady YoY, But Margin Target Just Got 200 Basis Points Cheaper

Q2 PAT fell 10.3% quarter-on-quarter despite 8.2% year-on-year growth. Management's response: ratchet down FY28 EBITDA margin guidance from 20% to 18–19%, signal capex stress ahead, and admit export logistics remain broken. The market has already priced it in.

11 Nov 2026 · 6 min read
Reported PAT

₹35.6 Cr

+8.2% YoY

Sequential PAT

₹35.6 Cr

-10.3% QoQ (implied)

Adjusted EBITDA margin

14.9%

+40 bps YoY

FY28 EBITDA target

18–19%

Cut 100–200 bps from prior 20%

Vishnu Chemicals posted a textbook steady-quarter on the headline: revenue up 7.1% year-over-year to ₹429.5 Cr, net profit up 8.2% to ₹35.6 Cr. But the quarter-on-quarter story tells a different tale. PAT fell 10.3% sequentially — signaling deceleration into Q2 despite strong H1 growth of 15.4%. The culprit is not operational: it is logistics. Management quantified export business pressure at ₹20–30 crore lost per quarter in leather sales, driven by geopolitical freight cost inflation (20–25% of leather export selling price). And on guidance, the company took an axe to forward expectations: FY28 EBITDA margin target ratcheted down from 20% (stated last quarter) to 18–19% effective this call. That is a 100–200 basis-point cut in one quarter — a material reset that signals management's conviction on near-term execution has weakened.

The tension: strong organic but margin headwinds are real

H1 FY27 grew revenue 15.4% year-over-year (₹862.3 Cr from ₹748.1 Cr in H1 FY26), implying Q1 was very strong and Q2 decelerated. EBITDA margin held at 14.9% — up 40 basis points year-over-year despite logistics drag — which shows underlying operational resilience. But the PAT margin compressed to 8.1% from implied 8.7% in H1, meaning Q2 felt the full brunt of freight cost inflation. Management's own math: logistics costs consumed 20.9% of export sales in Q2 versus 10.7% consolidated in Q1, a near doubling that eroded about 300 basis points of quarterly margin.

Management claims vs. what held up

Q2 revenue ~₹429.5 Cr, up 7% YoY

Delivered ₹429.5 Cr, 7.1% YoY. Confirmed.

Supported

EBITDA margin 14.9%, up 40 bps YoY

OPM 14.9% confirmed; margin expansion 40 bps YoY

Supported

PAT ₹35.57 Cr, up 8.2% YoY

PAT ₹35.6 Cr, 8.2% YoY, NPM 8.1%

Supported

FY28 EBITDA margin target 20% (from prior call)

This call: 18–19% for FY28. Cut of 100–200 bps.

Overstated (guidance reset downward)

Export sales down due to freight, ~₹20–30 Cr/quarter loss

Leather exports down YoY; freight impact 20–25% of price. Value loss acknowledged.

Supported

What changed on this call

Margin guidance downgrade (FY28 target 20% → 18–19%). The biggest signal. Prior call stated 20% EBITDA margin target by FY28; this call cuts it to 18–19% for the same fiscal year. That is a 100–200 basis-point reset in one quarter, citing macro headwinds, logistics drag, and execution risk on new ventures (DMSO, chromium JV) as the rationale. Credibility grade: B (hit Q2 numbers but reset forward guides lower).

Capex guidance raised (FY27 ₹200–250 Cr → next 12 months ₹300 Cr). Prior guidance was ₹200–250 Cr for full FY27; this call sets next 12 months at ₹300 Cr (implies ~₹490 Cr annualized vs. ₹250 Cr prior FY27 ceiling). H1 spent ₹190 Cr; remaining ~₹330 Cr over next 12 months. The step-up is driven by DMSO plant (greenfield, Odisha, ~₹250+ Cr), chromium metal JV (₹50 Cr via DCX partnership), and oxide/specialty chemical capacity. Peak debt expected ₹800–₹820 Cr mid-FY27.

Export outlook downgrade. Q1 FY27 assumed export stability; Q2 call now quantifies leather exports down significantly (₹20–30 Cr/quarter loss), recovery delayed to Q4 (timeline uncertain). This is a material re-forecast versus the prior quarter's baseline.

Domestic sales mix strategy gaining ground. Domestic sales now 58% of consolidated Q2 (vs. 45% in Q1), a deliberate shift to hedge export volatility. This supports organic growth resilience but signals management's caution on near-term export outlook.

Margin math and the catalyst timeline

Management is betting on three levers to recover from 14.9% (Q2) to 18–19% (FY28): (1) DMSO plant ramp (Q1 FY28 start): 10,000 tons/year capacity; targeting 50–60% operating level first year, 70% by year two. Gross margin 35–40%, EBITDA margin framed as 'very promising' but no specific guidance given until plant runs and customer approvals close. (2) Chromium metal JV (Q4 FY27 startup): 6,000 tons/year high-purity capacity via DCX partnership at Visakhapatnam. Targeting 20% EBITDA margin (volume-driven); 60–70% export-focused to aerospace/defense. (3) Backward integration payback: Barium capex complete (₹375 Cr); capacity utilization at 70%; margin recovery underway. Domestic specialty chemicals (oxide, acid) gaining share.

The timeline matters: Q4 FY27 (est. Jan 2027) is chromium metal startup; Q1 FY28 (Apr 2027) is DMSO ramp. That means FY28 margin target assumes both come online AND run at sufficient utilization within a 12-month window. Execution risk is real.

The bull-bear ledger
  • H1 FY27 revenue growth 15.4% YoY outpaces standalone 7.1% Q2, showing strong start to year

  • EBITDA margin resilience: 14.9% Q2 vs 14.5% YoY despite freight drag shows operational strength

  • Backward integration (barium) capex complete; payback underway; diversification into specialty chemicals working

  • Domestic sales mix (58%) growing faster than export; insulates from geopolitical freight volatility

  • Q2 PAT fell 10.3% QoQ despite YoY growth; near-term momentum faltering

  • FY28 margin guidance cut 100–200 bps in one quarter; signals execution/macro risk not fully baked into prior plan

  • Capex intensity rising (₹300 Cr next 12m); peak debt ₹800–₹820 Cr; ROI and cash generation at risk near-term

  • New venture margins deferred ('very early,' 'volume-driven'); DMSO and chromium profitability unproven at scale

  • Export leather recovery timeline (Q4) uncertain; if geopolitical tensions persist, ₹20–30 Cr/quarter loss continues

  • Working capital pressure: inventory +10 days to 72–73; if export recovery delayed, working capital tension persists

Risks, ranked by severity and holder concern

Logistics and geopolitical freight volatility persist

HIGH

Leather exports (42% of revenue mix) down ₹20–30 Cr/quarter due to freight at 20–25% of export price. Q4 recovery timeline uncertain. If West Asian tensions continue, margin pressure persists into FY28, undermining 18–19% target.

Capex execution slippage on new ventures (DMSO, chromium JV)

MEDIUM

DMSO plant (greenfield, Odisha) targeting Q1 FY28 ramp; chromium JV Q4 FY27 startup. Both are critical for margin recovery. Delays or cost overruns erode ROI and push debt peak beyond ₹800–₹820 Cr guidance.

New venture profitability underperforms (utilization, pricing)

MEDIUM

DMSO margins (35–40% gross, EBITDA 'very promising') and chromium (20% EBITDA 'volume-driven') are assumptions not yet validated. If either ramps below 50% utilization or faces pricing pressure, FY28 18–19% target misses.

Macro/commodity price volatility (sulfuric acid, energy, raw materials)

HIGH

Specialty chemicals (chrome, barium, strontium) are commodity-input-dependent. No hedging disclosed; margin recovery assumes commodity prices stabilize. Energy cost inflation pressures operating leverage.

Working capital pressure from delayed export recovery

MEDIUM

Inventory days up 10 days to 72–73 due to macro caution and elevated logistics costs. If export volume recovery delays beyond Q4, receivables days stretch, tightening cash and delaying debt paydown.

Market concentration in domestic auto/infra and export leather

MEDIUM

Domestic 58% tilted toward auto and infra (cyclical sectors); export 42% skewed toward leather (geopolitical sensitive). Strontium carbonate profitability below expectations despite ₹25 Cr Q1 revenue. Diversification incomplete.

How the street is positioned (and why the stock fell 24.66% from ATH)

The stock closed at ₹560.5 on day 1 of this report, down 24.66% from its all-time high of ₹744. It sits below all three moving averages (SMA20 ₹576.52, SMA50 ₹644.52, SMA200 ₹587.58), and RSI 40.4 signals neutral/oversold territory. Volume is normal; price trend is neutral. This drawdown is not a panic sell — it is a measured re-rating.

The market's logic is clear: the 20% → 18–19% margin guidance cut, combined with capex ramp to ₹300 Cr next 12 months and near-term logistics drag, erases near-term earnings lift. The stock has already repriced the downside. Institutional ownership is stable: FII at 2.51% (up 21 bps from Q1 FY27's 2.30%) and DII at 5.94% (up 22 bps from 5.72%). Promoter steady at 69.21%. Neither FII nor DII is bailing; both are incrementally adding. This suggests sophisticated investors see value at current levels, betting the capex and new ventures deliver the medium-term recovery.

Valuation context: the 24.66% drawdown from ATH leaves room for upside if FY28 margins beat 18–19% (unlikely near-term, but possible by late FY28) or if capex generates ROI faster than feared. But the stock is not yet cheap enough to offset execution risk — it is fairly valued for a 'show me' story.

The debate

The honest read: Vishnu delivered a steady quarter operationally but signaled execution caution via guidance reset and capex step-up. The company is navigating near-term logistics headwinds (Q2–Q4) while betting capex and new ventures drive a multi-year margin uplift (FY28 onwards). The near-term risk (logistics persist, capex overrun, utilization misses) outweighs the medium-term upside (DMSO, chromium, backward integration). The market has already priced in the downside (stock -24.66% from ATH), and institutional ownership is stable. At ₹560, the stock is a Hold — not a buy until capex ROI materializes or export volumes recover, but not a sell either because the underlying story is credible. The next quarter will clarify: if Q3 margins trend upward or leather volumes stabilize, the upside re-rates; if Q3 margins compress further, the stock tests ₹480–₹500.

What to watch next
  • 1 · Q3 EBITDA margin trend and export volume stabilization

    Management guided Q3 as 'positive trend vs Q2' but offered wide ranges (15–18% H2 EBITDA margin). The key: does Q3 margin improve QoQ? Leather export recovery is critical; if ₹20–30 Cr/quarter loss persists, margin compression accelerates. Watch for management commentary on Q4 recovery timeline (certain or uncertain).

  • 2 · DMSO plant customer approvals and ramp visibility

    DMSO plant is expected Q1 FY28 startup (Apr 2027, ~6 months away). By Q3 FY27 earnings (late Jan 2027), management should provide update on customer approvals, pricing, and first-year utilization target. No visibility = execution risk.

  • 3 · Capex tracking and debt trajectory

    H1 capex ₹190 Cr; next 12 months ₹300 Cr. Q3 disclosure will show YTD capex and revised FY27 outlook. If capex accelerates or overshoots, peak debt could breach ₹820 Cr guidance, pressuring credit metrics and free cash flow. Watch for debt/EBITDA trend and management commentary on refinancing risk.

Vishnu Chemicals is a steady-operator hit by near-term headwinds (logistics, export volatility, capex intensity) that management believes it can overcome via new ventures and backward integration payback. The 7.1% Q2 revenue growth and 14.9% EBITDA margin are resilient on the operational level; the risk is that margins stay pinned at 14–15% through FY28 if execution slips or macro headwinds persist. The stock has repriced from ₹744 to ₹560 — a fair re-rating for the guidance reset, but not yet cheap enough to offset the execution bet ahead. Hold and watch for Q3 margin inflection and capex ROI color by late January.

Informational and educational content only. Not investment advice.